Revvity's Q1: Strong Growth, China Divestment, AI Innovations

Revvitys Q1 2026 report shows robust growth, with 3% organic growth and 23.6% adjusted operating margins, surpassing expectations. The company is divesting its China immunodiagnostics business, aiming to close by end of 2023, which will boost Q1 growth to 6% and margins to 24%. End markets performed well, with pharma, biotech, and academic customers showing growth, and reproductive health surging. Revvity is investing in AI-powered tools for drug design and lab validation work, with updated full-year guidance reflecting the divestment. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/687509683a523b26